Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment.

BACKGROUND: Chronic heart failure (CHF) is a major cause of morbidity and mortality that requires a novel approach to therapy. Perhexiline is an antianginal drug that augments glucose metabolism by blocking muscle mitochondrial free fatty acid uptake, thereby increasing metabolic efficiency. We asse...

Full description

Bibliographic Details
Main Authors: Lee, L, Campbell, R, Scheuermann-Freestone, M, Taylor, R, Gunaruwan, P, Williams, L, Ashrafian, H, Horowitz, J, Fraser, A, Clarke, K, Frenneaux, M
Format: Journal article
Language:English
Published: 2005

Similar Items